Cargando…

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors

BACKGROUND: Although factor Xa inhibitors have become a popular choice for chronic oral anticoagulation, effective drug reversal remains difficult due to a lack of specific antidote. Currently, 4-factor prothrombin complex concentrate (4F-PCC) is considered the treatment of choice for factor Xa inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Jing, Bukanova, Elena N., Akhtar, Shamsuddin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001072/ https://www.ncbi.nlm.nih.gov/pubmed/29942519 http://dx.doi.org/10.1186/s40560-018-0303-y

Ejemplares similares

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
por: Schultz, Nina Haagenrud, et al.
Publicado: (2017)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
por: Lu, Genmin, et al.
Publicado: (2020)

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
por: Schultz, Nina Haagenrud, et al.
Publicado: (2018)

Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models
por: Ghosh, Subhajit, et al.
Publicado: (2021)

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban‐treated patients in vitro
por: Schultz, Nina H., et al.
Publicado: (2017)

Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
por: Jaspers, Tessa, et al.
Publicado: (2021)

Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study
por: Singer, Adam J., et al.
Publicado: (2023)

Efficacy of idarucizumab, prothrombin complex concentrate (PCC) and activated PCC to reverse the anticoagulatory potential of dabigatran in a porcine polytrauma model
por: Honickel, M, et al.
Publicado: (2015)

Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
por: Sutton, S. Scott, et al.
Publicado: (2023)

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study
por: Dobesh, Paul P., et al.
Publicado: (2023)

Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
por: Sutton, S. Scott, et al.
Publicado: (2023)

Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic review
por: Costa, Olivia S, et al.
Publicado: (2020)

Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
por: Margraf, David J., et al.
Publicado: (2022)

Four-factor prothrombin complex concentrate (Beriplex® P/N) is superior to three-factor prothrombin complex concentrate for reversal of coumarin anticoagulation
por: Herzog, E, et al.
Publicado: (2015)

Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department
por: Maguire, Michelle, et al.
Publicado: (2019)

A Rare Case of Skin Necrosis Following Extravasation of Prothrombin Complex Concentrate (PCC) Infusion During Warfarin Reversal
por: Smith, Emma C, et al.
Publicado: (2023)

Optimal Dosage and Administration Practices for Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate
por: Rhoney, Denise H., et al.
Publicado: (2020)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Acquired deficiency of prothrombin complex coagulation factors in major bleeding is a therapeutic indication of 4‐factor prothrombin complex concentrates
por: Wiedermann, Christian J.
Publicado: (2020)

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
por: Grottke, Oliver, et al.
Publicado: (2016)

Prothrombin complex concentrate (PCC) for treatment of trauma-induced coagulopathy: systematic review and meta-analyses
por: Hannadjas, Ioannis, et al.
Publicado: (2023)

Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage
por: Troyer, Camille, et al.
Publicado: (2022)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
por: Wójcik, Cezary, et al.
Publicado: (2009)

Binding modes of prothrombin cleavage site sequences to the factor Xa catalytic triad: Insights from atomistic simulations
por: Li, Jiachen, et al.
Publicado: (2022)

PROTHROMBIN COMPLEX CONCENTRATE  IN EMERGENCY DEPARTMENT
por: Nesek Adam, Višnja, et al.
Publicado: (2022)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding
por: Holt, Tara, et al.
Publicado: (2018)

Reversibility of Apixaban Anticoagulation with a Four‐Factor Prothrombin Complex Concentrate in Healthy Volunteers
por: Nagalla, S, et al.
Publicado: (2016)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
por: Shaw, Joseph R., et al.
Publicado: (2023)

Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
por: Chapman, Scott A, et al.
Publicado: (2014)

INR and vitamin K–dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma
por: Hood, Christopher, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kjckvhcppl44et48tp9rq4l93j